Nasdaq: INTS

Intensity Therapeutics, Inc. (INTS)

Intensity Therapeutics, Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker INTS. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
INTS
Exchange
Nasdaq
SEC CIK
1567264
Official filings
SEC EDGAR

Research INTS

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Intensity Therapeutics, Inc.'s stock ticker?

Intensity Therapeutics, Inc. trades under the ticker symbol INTS on Nasdaq. Its SEC Central Index Key (CIK) is 1567264.

Where can I read Intensity Therapeutics, Inc.'s SEC filings?

The INTS SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Intensity Therapeutics, Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze INTS's financial statements?

The INTS Financials page shows Intensity Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does INTS compare with its peers and the market?

The INTS Peer Comparison page lines Intensity Therapeutics, Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.